A phenylbutazone dose-finding study in rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic inflammatory disorder.
• Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) used for RA management.

Purpose of the Study:

• To determine the minimum effective dose of phenylbutazone in patients with rheumatoid arthritis.
• To investigate the relationship between drug dosage, plasma levels, and patient response.

Main Methods:

• A double-blind study involving 32 patients with rheumatoid arthritis.
• Evaluation of eight different daily doses of phenylbutazone ranging from 90 mg to 450 mg.
• Monitoring for adverse reactions and assessing patient response to treatment.

Main Results:

• The most efficacious dose of phenylbutazone was determined to be 300 mg/day.
• Doses lower than 300 mg/day resulted in incomplete therapeutic benefit.
• Higher doses did not yield further improvements, and no correlation was found between plasma levels and adverse reactions or patient response.

Conclusions:

• A daily dose of 300 mg of phenylbutazone is identified as the minimum effective dose for rheumatoid arthritis.
• Plasma concentrations of phenylbutazone and oxyphenbutazone do not predict treatment efficacy or adverse events in RA patients.